ARRY:NSD-Array BioPharma Inc. (USD)

EQUITY | Solar | NASDAQ Global Market

Last Closing

USD 11.11

Change

+0.37 (+3.45)%

Market Cap

USD 1.31B

Volume

4.76M

Analyst Target

USD 44.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Solar

Symbol Name Price(Change) Market Cap
FSLR First Solar Inc

-17.95 (-6.16%)

USD 28.62B
ENPH Enphase Energy Inc

-5.11 (-3.94%)

USD 18.13B
NXT Nextracker Inc. Class A Common..

-1.28 (-2.11%)

USD 8.08B
RUN Sunrun Inc

-0.61 (-4.40%)

USD 2.98B
SEDG SolarEdge Technologies Inc

-3.41 (-7.88%)

USD 2.63B
SHLS Shoals Technologies Group Inc

-0.31 (-4.57%)

USD 1.16B
CSIQ Canadian Solar Inc

-1.03 (-5.70%)

USD 1.15B
SPWR SunPower Corporation

-0.31 (-9.82%)

USD 0.58B
SMXT Solarmax Technology Inc. Commo..

-0.61 (-11.60%)

USD 0.27B
ZEO Zeo Energy Corp

+0.18 (+4.04%)

USD 0.18B

ETFs Containing ARRY

ZERO:PA 3.92 % 0.00 %

N/A

N/A
CTEX ProShares S&P Kensho Clea.. 3.88 % 0.00 %

-0.84 (-1.91%)

USD 3.56M
TANN:AU BetaShares Solar ETF 3.77 % 0.00 %

-0.07 (-1.91%)

N/A
ISUN:LSE Invesco Solar Energy UCIT.. 3.65 % 0.00 %

-0.45 (-1.91%)

USD 0.07B
S0LR:F Invesco Solar Energy UCIT.. 3.63 % 0.00 %

-0.35 (-1.91%)

USD 0.07B
S0LR:XETRA Invesco Solar Energy UCIT.. 3.63 % 0.00 %

-0.28 (-1.91%)

USD 0.07B
SOLR:SW Invesco Solar Energy UCIT.. 3.63 % 0.00 %

-0.61 (-1.91%)

USD 0.07B
RAYS:LSE Invesco Solar Energy UCIT.. 3.40 % 0.00 %

-24.80 (-1.91%)

USD 0.07B
RA7Z:XETRA Global X Solar UCITS ETF .. 2.68 % 0.00 %

-0.07 (-1.91%)

USD 3.23M
RAYZ:SW Global X Solar UCITS ETF .. 2.68 % 0.00 %

-0.14 (-1.91%)

USD 3.48M
PBD Invesco Global Clean Ener.. 1.12 % 0.75 %

-0.10 (-1.91%)

USD 0.12B
GCED:LSE Invesco Markets II plc - .. 1.06 % 0.00 %

N/A

USD 1.51M
GCEX:LSE Invesco Markets II plc - .. 1.06 % 0.00 %

-55.60 (-1.91%)

USD 1.51M
TAN Invesco Solar ETF 0.00 % 0.65 %

-1.32 (-1.91%)

USD 1.20B
HCLN:CA Harvest Clean Energy ETF .. 0.00 % 0.00 %

-0.16 (-1.91%)

CAD 0.03B
GCLE:LSE Invesco Markets II plc - .. 0.00 % 0.00 %

-0.25 (-1.91%)

USD 0.04B
GCLX:LSE Invesco Markets II plc - .. 0.00 % 0.00 %

-10.70 (-1.91%)

USD 0.04B
CLMT:CA 0.00 % 0.00 %

N/A

N/A
RAYS Global X Solar ETF 0.00 % 0.00 %

-0.28 (-1.91%)

USD 6.39M
RAYG:LSE Global X Solar UCITS ETF .. 0.00 % 0.00 %

-0.04 (-1.91%)

USD 3.48M
ZER0:XETRA 0.00 % 0.00 %

N/A

N/A
CT3C:XETRA Global X CleanTech UCITS .. 0.00 % 0.00 %

-0.13 (-1.91%)

USD 2.37M
RAYZ:LSE Global X Solar UCITS ETF .. 0.00 % 0.00 %

-0.11 (-1.91%)

USD 3.48M
WRNW:XETRA WisdomTree Renewable Ener.. 0.00 % 0.00 %

-0.23 (-1.91%)

USD 1.19M
RENW:SW L&G Clean Energy UCITS ET.. 0.00 % 0.00 %

-0.18 (-1.91%)

USD 0.25B

Market Performance

  Market Performance vs. Industry/Classification (Solar) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.87% 55% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.87% 55% F 16% F
Trailing 12 Months  
Capital Gain -53.92% 59% D- 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.92% 59% D- 17% F
Trailing 5 Years  
Capital Gain -57.92% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.92% 40% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -6.52% 35% F 31% F
Dividend Return -6.52% 35% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.00% 65% D 28% F
Risk Adjusted Return -11.43% 35% F 34% F
Market Capitalization 1.31B 77% C+ 78% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Solar) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.26 33% 33%
Price/Book Ratio 7.57 25% 15%
Price / Cash Flow Ratio 7.03 36% 34%
Price/Free Cash Flow Ratio 10.12 36% 26%
Management Effectiveness  
Return on Equity 19.68% 91% 89%
Return on Invested Capital 14.31% 88% 84%
Return on Assets 6.28% 83% 89%
Debt to Equity Ratio 108.26% 25% 21%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.